Ivabradine
- Generic Name
- Ivabradine
- Brand Names
- Corlanor, Lancora, Procoralan, Corlentor, Ivabradine Accord, Ivabradine Anpharm, Ivabradine Zentiva
- Drug Type
- Small Molecule
- Chemical Formula
- C27H36N2O5
- CAS Number
- 155974-00-8
- Unique Ingredient Identifier
- 3H48L0LPZQ
- Background
Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats ...
- Indication
Ivabradine is indicated by the FDA to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤35%, who are in sinus rhythm with resting heart rate ≥70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contrain...
- Associated Conditions
- Chronic Heart Failure (CHF), Chronic Stable Angina Pectoris, Left Ventricular Dysfunction, Chronic, stable, symptomatic Heart Failure
- Associated Therapies
- -
Effect of Ivabradine in Lowering Heart Rate and Quality of Life in Chronic Heart Failure Patients
- Conditions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Getz Pharma
- Target Recruit Count
- 50
- Registration Number
- NCT03710057
Early Use of Ivabradine in Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2018-10-10
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 50
- Registration Number
- NCT03701880
- Locations
- 🇪🇬
El Demerdash Hospital, Cairo, Egypt
Ivabradine to Prevent Anthracycline-induced Cardiotoxicity
- Conditions
- Interventions
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2019-04-02
- Lead Sponsor
- University of Sao Paulo
- Target Recruit Count
- 160
- Registration Number
- NCT03650205
- Locations
- 🇧🇷
Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, SP, Brazil
Ivabradine in Stage D Heart Failure Patients on Chronic Inotropes
- First Posted Date
- 2018-08-15
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- University of Maryland, Baltimore
- Registration Number
- NCT03631654
An Interventional Study to Evaluate the Effect of Ivabradine on Exercise Capacity in Heart Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2018-08-07
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- Amgen
- Registration Number
- NCT03619187
Pharmacokinetic Drug-Drug Interaction Between Bisoprolol and Ivabradine in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2018-04-02
- Last Posted Date
- 2018-04-02
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 18
- Registration Number
- NCT03485482
- Locations
- 🇪🇬
Faculty of Pharmacy, Cairo, Egypt
A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction.
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 30
- Registration Number
- NCT03456856
- Locations
- 🇺🇸
Research Site, Buffalo, New York, United States
Effect of Ivabradine on Exercise Capacity After Heart Transplantation
- Conditions
- Interventions
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Finn Gustafsson
- Target Recruit Count
- 35
- Registration Number
- NCT03405831
- Locations
- 🇩🇰
Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
Effect of Ivabradine in Stage D HF/Cardiogenic Shock Patients on Dobutamine
- Conditions
- Interventions
- First Posted Date
- 2018-01-02
- Last Posted Date
- 2019-05-23
- Lead Sponsor
- Loyola University
- Target Recruit Count
- 40
- Registration Number
- NCT03387605
- Locations
- 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome
- Conditions
- Interventions
- First Posted Date
- 2017-06-09
- Last Posted Date
- 2021-06-29
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 37
- Registration Number
- NCT03182725
- Locations
- 🇺🇸
University of California, San Diego, La Jolla, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.